AB Science develops compounds for therapeutic use in various diseases, including neurodegenerative disorders, oncology, inflammatory diseases, and viral diseases. The company is self-described as having breakthrough mechanisms of action in its products.

AB Science

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

WordPress

President

Albert Ahn

Sales and Marketing Manager Europe

Alexander Utech

Project Manager Biotechnology

Gérald Gaibelet

North Central Region Manager

KateLynn Dulinsky

Senior Operations Manager at Dott

Pierre d'Anselme

Global Chief Medical Officer (CMO)

Christian Fassotte

Senior Researcher Medicinal Chemistry and Cheminformatics

Dmytro Atamanyuk

Chief Scientific Officer, Drug Discovery

Laurent Gros

Chief Financial Officer

Laurent Guy

Western Region Representative

Leah Repsher

Alain Moussy

Co-Founder and CEO

Jean-Pierre Kinet

Founder &Board member

Europe Public Companies With Less Than $50M in Revenue

Ile-de-France Companies With More Than 100 Employees

Biotechnology Companies With More Than 100 Employees

Pharmaceutical Companies With Less Than $500M in Revenue (Top 10K)

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. They are innovators and scientific entrepreneurs in the field of life science.

Post-IPO Equity - AB Science

European Investment Bank

Post-IPO Debt - AB Science

Paris

Ile-de-France

France

Europe

AB Science: European patent accepted

BRIEF—EMA re-affirms non-renewal of masitinib and Translarna authorizations

AB Science: settlement of capital increase

AB Science: 5.0 ME capital increase

AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

AB Science reports patent for tubulin polymerization inhibitors

AB Science annonce des résultats positifs de son étude de Phase 2 évaluant le masitinib dans la Covid-19

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

Nigeria

Africa

India

Asia

Pakistan

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

AB Science S.A.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 27, 2024 4:56 PM	97b0e1a8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 27, 2024 4:56 PM	2821442f
crunchbase trigger	general	Oct 29, 2024 5:10 PM	ea810a80
crunchbase profile	general	Oct 29, 2024 11:11 PM	d3be17c1
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	a4f7baea
peers	general	Sep 27, 2024 4:56 PM	12272a69
news basic	general	Sep 27, 2024 4:56 PM	51dc7593
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AB-SCIENCE

AB Science

Last Close

0.80

25/11 08:59

Market Cap

57.80M

Beta: -

Volume Today

5.88K

Avg: -